Association analysis and the clinical significance of BRAF gene mutations and ultrasound features in papillary thyroid carcinoma

Liu,Ying; He,Lingyun; Yin,Guobing; Cheng,Long; Zeng,Bin; Cheng,Juan; Yang,Lu

doi:10.3892/ol.2019.10641

Association analysis and the clinical significance of BRAF gene mutations and ultrasound features in papillary thyroid carcinoma

Authors:
- Ying Liu
- Lingyun He
- Guobing Yin
- Long Cheng
- Bin Zeng
- Juan Cheng
- Lu Yang
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China, Department of Scientific Research and Education Section, Chongqing Health Center for Women and Children, Chongqing 401120, P.R. China, Department of Ultrasound, Second Affiliated Hospital of Chongqing Medical University and Chongqing Key Laboratory of Ultrasound Molecular Imaging, Chongqing 400010, P.R. China
Published online on: July 22, 2019 https://doi.org/10.3892/ol.2019.10641
Pages: 2995-3002
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the associations between the B‑Raf proto‑oncogene serine/threonine kinase (BRAF)V600E mutation and conventional and contrast‑enhanced ultrasonographic features in patients with papillary thyroid carcinoma (PTC), and to subsequently investigate the clinical value of these associations. In total, 207 thyroid nodules (diameter ≤2 cm) were selected. Conventional ultrasound, contrast‑enhanced ultrasound, BRAFV600E mutational analysis and ultrasound‑guided fine‑needle aspiration biopsy were preoperatively performed, and histopathological assessment of PTC was postoperatively confirmed. The nodules were divided into 2 groups based on the BRAFV600E mutational analysis, namely the mutant or the wild‑type variant groups, and the association analyses of the ultrasonographic features between these 2 groups were performed. Overall, 74.9% (155/207) of the PTC nodules had the BRAFV600E mutation, while 25.1% (52/207) had the wild‑type BRAF allele. The 2 groups were analyzed using univariate logistic regression analysis, which demonstrated no significant differences regarding morphology, boundary, hypoechogenicity of the nodules, blood flow signal, enhancement uniformity, enhancement degree and clearance time (P>0.05). Moreover, the 2 groups demonstrated significant differences regarding the aspect ratio, microcalcification, nodule size following enhancement, enhancement mode and enhancement time (P<0.05). A multivariate logistic regression analysis was performed to further validate the association of these features with the BRAFV600E mutation; however, only microcalcification [odds ratio (OR), 2.256; 95% confidence interval (CI), 1.160‑5.500; P=0.020] and nodule size following enhancement (OR, 2.119; 95% CI, 1.039‑4.321; P=0.039) were associated with the BRAF mutational status. The associations found between the two ultrasonographic features and BRAFV600E mutation indicate that they can predict the BRAF mutational status to provide a reliable basis for clinical diagnosis and treatment.

View Figures

View References

1	Du L, Li R, Ge M, Wang Y, Li H, Chen W and He J: Incidence and mortality of thyroid cancer in China, 2008–2012. Chin J Cancer Res. 31:144–151. 2019. View Article : Google Scholar : PubMed/NCBI
2	Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ and Nikiforov YE: The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 99:E276–E285. 2014. View Article : Google Scholar : PubMed/NCBI
3	Czarniecka A, Oczko-Wojciechowska M and Barczyński M: BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 5:495–505. 2016. View Article : Google Scholar : PubMed/NCBI
4	Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, Xu H, Xing M and Qu S: BRAFV600E mutation in papillary thyroid microcarcinoma: A meta-analysis. Endocr Relat Cancer. 22:159–168. 2015. View Article : Google Scholar : PubMed/NCBI
5	Czarniecka A, Kowal M, Rusinek D, Krajewska J, Jarzab M, Stobiecka E, Chmielik E, Zembala-Nozynska E, Poltorak S, Sacher A, et al: The risk of relapse in papillary thyroid cancer (PTC) in the context of BRAFV600E mutation status and other prognostic factors. PLoS One. 10:e01328212015. View Article : Google Scholar : PubMed/NCBI
6	Chen Y, Sadow PM, Suh H, Lee KE, Choi JY, Suh YJ, Wang TS and Lubitz CC: BRAF(V600E) is correlated with recurrence of papillary thyroid microcarcinoma: A systematic review, Multi-institutional primary data analysis, and meta-analysis. Thyroid. 26:248–255. 2016. View Article : Google Scholar : PubMed/NCBI
7	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Brito JP, Ito Y, Miyauchi A and Tuttle RM: A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid. 26:144–149. 2016. View Article : Google Scholar : PubMed/NCBI
10	Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 309:1493–1501. 2013. View Article : Google Scholar : PubMed/NCBI
11	Prescott JD: BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 152:984–990. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X and Gao M: Papillary microcarcinoma of the thyroid: Clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol. 20:2266–2273. 2013. View Article : Google Scholar : PubMed/NCBI
13	Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiórkiewicz E, Chodurska R, Pięciak L and Góźdź S: The BRAF(V600E) mutation in papillary thyroid microcarcinoma: Does the mutation have an impact on clinical outcome. Clin Endocrinol (Oxf). 80:899–904. 2014. View Article : Google Scholar : PubMed/NCBI
14	Moon HJ, Kim EK, Chung WY, Shin DY and Kwak JY: BRAF mutation in fine needle aspiration specimens as a potential predictor for persistence/recurrence in patients with classical papillary thyroid carcinoma larger than 10 mm at a BRAF mutation prevalent area. Head Neck. 37:1432–1438. 2015. View Article : Google Scholar : PubMed/NCBI
15	Peyssonnaux C and Eychène A: The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell. 93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI
16	Liu C, Chen T and Liu Z: Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: A meta-analysis. World J Surg Oncol. 14:2412016. View Article : Google Scholar : PubMed/NCBI
17	Zhang B, Jiang YX, Dai Q, et al: Prospective observation of contrast-enhanced patterns of thyroid nodules with SonoVue. Chin J Med Imaging Technol. 26:844–847. 2010.
18	Yang YJ, Jian-Min L and Wang BC: Study of relationship between VEGF expression and tumor progress of primary hepatocellular carcinoma. China J Modern Med. 15:408–412. 2005.
19	Bartolotta TV, Midiri M, Galia M, Runza G, Attard M, Savoia G, Lagalla R and Cardinale AE: Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound: Initial results. Eur Radiol. 16:2234–2241. 2006. View Article : Google Scholar : PubMed/NCBI
20	Zhou Q, Jiang J, Du XP, et al: Value of contrast-enhanced ultrasound in diagnosis of thyroid papillary carcinoma. Chin J Ultrasound Med. 27:595–597. 2011.
21	Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, Correas JM, Darge K, Dietrich C, D'Onofrio M, et al: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)-update 2008. Ultraschall Med. 29:28–44. 2008. View Article : Google Scholar : PubMed/NCBI
22	Cong X, Zhao S, Wang Y, et al: Ultrasound features of braf t1799a gene mutation papillary thyroid carcinoma. Med J Qilu. 29:201–212. 2014.
23	Kabaker AS, Tublin ME, Nikiforov YE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Carty SE and Yip L: Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. Thyroid. 22:585–589. 2012. View Article : Google Scholar : PubMed/NCBI
24	Sastre-Marcos J, Val-Zaballos FD, Cortes-Muñoz C, Campos-Martin Y, Aso-Manso S, Jaen-Diaz I, Vicente-Delgado A and Lopez-Lopez J: BRAF V600E positive papillary thyroid carcinoma is associated with suspicious ultrasound feature. Endocrine. 37:EP8502015.
25	Luo ZY, Hong YR, Wen Q, et al: Associations of the BRAF V600E mutation with sonographic features in patients with papillary thyroid carcinoma. Chin J Ultrasonogr. 25:785–789. 2016.
26	Li Q, Yuan J, Wang Y and Zhai Y: Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma. Oncol Lett. 14:1439–1444. 2017. View Article : Google Scholar : PubMed/NCBI
27	Moon HJ, Kim EK, Yoon JH and Kwak JY: Clinical implication of elastography as a prognostic factor of papillary thyroid microcarcinoma. Ann Surg Oncol. 19:2279–2287. 2012. View Article : Google Scholar : PubMed/NCBI
28	Jin ZQ, Lin MY, Hu WH, Li WY and Bai SJ: Gray-Scale ultrasonography combined with elastography imaging for the evaluation of papillary thyroid microcarcinoma: As a prognostic clinicopathology factor. Ultrasound Med Biol. 40:1769–1777. 2014. View Article : Google Scholar : PubMed/NCBI